TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR 11 12 9 17 26 PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47:

Slides:

Advertisements

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Advertisements

IVD Validation and Regulation in Rx/Dx Combinations

Triple-Negative Breast Cancer

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

Supplemental Figure 1 A No. at risk T T T

Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.

Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Performance measures Morten Nielsen, CBS, BioCentrum, DTU.

Introduction to Biomedical Statistics. Signal Detection Theory What do we actually “detect” when we say we’ve detected something?

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Supplementary Figure 1. Supplementary Figure 2 All patients CharacteristicN% Median Age of patients 58 yrs ER Positive Negative PR Positive.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.

Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P

Diagnostic Test Characteristics Professor Mobeen Iqbal Shifa College of Medicine.

Ab hg fe d c Supplementary Figure 1 Supplementary figure 1: Validation of the ERRα antibody used for immunohistochemical analysis. Control MCF7 breast.

Sensitivity:DISEASE Specificity:PRESENTABSENT TEST RESULTS POSITIVEAbA+b NEGATIVECdC+d a+cb+da+b+c+d Lets recall the 2x2 contingency table Probability.

Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.

Treatment with ipilimumab

Epigenetic Regulation of Cancer Stem Cell Genes in Triple-Negative Breast Cancer Naofumi Kagara, Kelly T. Huynh, Christine Kuo, Hideyuki Okano, Myung.

Improved diagnosis, therapy and outcomes for patients with CUP

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

What Are Clinical Trials?

Treatment with ipilimumab

a b SUM149PT Motility Invasion C V C V

Arpan Mohanty, Sebhat Erqou, Kathleen A

Flavia D. Mendes, Ayako Suzuki, Schuyler O. Sanderson, Keith D

تحليل الحساسية Sensitive Analysis.

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

C. Allison Stewart, Lauren Averett Byers Cancer Cell

Supplemental Figure. Passing & Bablok regression graphs for each 25(OH)D assay compared with ID-XLC-MS/MS in each clinical subject group. R is shown in.

Figure 1. Table for calculating the accuracy of a diagnostic test.

CDK4/6 Biomarkers: Issues and Opportunities

Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis

Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis Ashwani K. Singal, Amanpal Singh, Sathya.

Evaluation of the Clinical Usefulness of Critical Patient Severity Classification System and Glasgow Coma Scale for Neurological Patients in Intensive.

Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis Jeremy.

Targeting T Cell Co-receptors for Cancer Therapy

Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study Craig.

A Risk Prediction Model for Invasive Fungal Disease in Critically Ill Patients in the Intensive Care Unit Fangyi Li, Minggen Zhou, Zijun Zou, Weichao.

Response to Carfilzomib Therapy

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease Patrick Chamouard, Zoe Richert, Nicolas Meyer, Gabriel Rahmi,

Supplemental Figure 1 Patient 2.

Triple‐negative human breast cancers specifically express high levels of nuclear HMGA2, whose expression has clinical relevance and predicts recurrence‐free.

C. Allison Stewart, Lauren Averett Byers Cancer Cell

CDK4/6 Biomarkers: Issues and Opportunities

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Clinical and Molecular Factors Associated With Histologic Response to Topical Steroid Treatment in Patients With Eosinophilic Esophagitis Swathi Eluri,

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Predicting Breast Cancer by Applying Deep Learning to Linked Health Records and Mammograms The algorithm predicted future breast cancer based on the index.

Induction of apoptosis by nelfinavir and bortezomib

Scoring of Coronary Artery Disease Characteristics on Coronary CT Angiograms by Using Machine Learning For prediction of all-cause mortality on the basis.

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

Tyrosine kinase inhibitors

Inclusion of Gene-Gene and Gene-Environment Interactions Unlikely to Dramatically Improve Risk Prediction for Complex Diseases Hugues Aschard, Jinbo.

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

Prof Matt Smalley, Director

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

* OS >3yr with No Next Line * * * * *

Presentation transcript:

TREATED RESPONDER 8 TREATED NONRESPDR 6 14 UNTREATED RESPONDER 1 UNTREATED NONRESPDR PR (IHC)- PATIENTS (N=26) Ln(ER  ) mRNA level ≥ 12.47: AUC =0.824, p=0.02 ER  mRNA positive negative TOTAL PRESENT ABSENT CLINICAL BENEFIT Sensitivity = 8/9 (89%) Specificity = 11/17 (65%) Positive Predictive Value = 8/14 (57%) TOTAL Ln(ER  ) mRNA > 12.47: AUC=0.824 (.639, 1.00) P= % - Specificity Sensitivity Supplemental Figure 3A

TREATED RESPONDER 7 TREATED NONRESPDR 5 12 UNTREATED RESPONDER 2 UNTREATED NONRESPDR BRCA1 mRNA positive negative TOTAL PRESENTABSENT CLINICAL BENEFIT Sensitivity = 7/9 (78%) Specificity = 12/17 (71%) Positive Predictive Value = 7/12 (64%) TOTAL Ln(BRCA-1) mRNA > 11.14: AUC=0.817 (.629, 1.00) P= % - Specificity Sensitivity PR (IHC)- PATIENTS (N=26) Ln(BRCA1) mRNA level ≥ 11.14: AUC= 0.817, p= Supplemental Figure 3B

TREATED RESPONDER 7 TREATED NONRESPDR 0 7 UNTREATED RESPONDER 2 UNTREATED NONRESPDR PR (IHC)- PATIENTS (N=26) Ln(BRCA1 mRNA) ≥ Ln(ER  mRNA level) Ln(BRCA1 mRNA) > – 0.31 Ln(ER  mRNA): AUC=0.902 (.757, 1.00) P= % - Specificity Sensitivity ER  BRCA1 mRNA positive negative TOTAL PRESENTABSENT CLINICAL BENEFIT Sensitivity = 7/9 (78%) Specificity = 17/17 (100%) Positive Predictive Value = 7/7 (100%) TOTAL Supplemental Figure 3C